Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.

You may also be interested in...



Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin

Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.

Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin

Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.

Sanofi-Aventis, P&G To Continue Actonel Collaboration

The companies’ new agreement covers R&D and commercial efforts supporting the osteoporosis therapy, Sanofi-Aventis says. Procter & Gamble also will co-promote risedronate in “additional territories.”

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel